Log in
Cryotherapeutic agent

Nitrogen

Nitrogen, particularly in its liquid form, is a cryotherapeutic agent used for the destruction of abnormal tissue through extreme cold application. It is most commonly employed in dermatology for removal of warts, skin tags, and superficial lesions. The key testable fact is that liquid nitrogen achieves temperatures of -196°C, causing intracellular ice crystal formation and cell death.

Practice questionsHigh-yield facts
Drug classCryotherapeutic agent
MechanismCellular destruction via intracellular ice crystal formation
Main usesWart removal, actinic keratosis, seborrheic keratosis treatment
Key adverse effectPain, blistering, hypopigmentation at application site
6 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Liquid nitrogen functions as a cryotherapeutic agent through rapid tissue freezing. When applied to tissue, it achieves temperatures of approximately -196°C (-320°F), causing immediate cellular damage through multiple mechanisms.

The primary mechanism involves intracellular ice crystal formation. Rapid freezing causes water within cells to crystallize, mechanically disrupting cellular membranes and organelles. The thaw phase that follows produces additional damage through osmotic stress as extracellular ice melts.

Vascular stasis occurs as extreme cold damages endothelial cells lining blood vessels, leading to thrombosis and ischemic necrosis of the frozen tissue. This secondary mechanism ensures complete tissue destruction even in cells that survive the initial freeze.

Additional effects include protein denaturation, disruption of cell membrane lipid bilayers, and induction of apoptosis in surviving peripheral cells. The depth of tissue destruction depends on freeze duration, number of freeze-thaw cycles, and application technique.

High-yield for exams
  • Liquid nitrogen achieves -196°C, causing cellular death through intracellular ice crystal formation and vascular stasis
  • Two freeze-thaw cycles are more effective than single prolonged freeze for wart and actinic keratosis treatment
  • Hypopigmentation is the most common long-term adverse effect, particularly problematic in darker skin types (Fitzpatrick IV-VI)
  • Absolute contraindication: cryoglobulinemia, cold urticaria, and cold agglutinin disease due to systemic cold sensitivity
  • Never cryotherapy suspected melanoma—tissue destruction prevents histopathologic diagnosis required for malignancy
  • Freeze halo should extend 1-2 mm beyond visible lesion margin for adequate treatment depth
  • Digital nerve damage risk: avoid aggressive treatment on lateral aspects of fingers and toes
  • Plantar warts require longer freeze times (20-30 seconds) due to thick overlying hyperkeratotic tissue

Indications

Liquid nitrogen cryotherapy is indicated for numerous benign and premalignant dermatologic conditions:

Benign lesions

  • Verruca vulgaris (common warts) and plantar warts
  • Seborrheic keratoses
  • Skin tags (acrochordons)
  • Dermatofibroma
  • Molluscum contagiosum
  • Angiomas and telangiectasias

Premalignant lesions

  • Actinic keratoses (solar keratoses)
  • Lentigo maligna (in selected cases)
  • Bowen disease (squamous cell carcinoma in situ)

Other applications

  • Keloid treatment (adjunct therapy)
  • Prurigo nodularis
  • Lentigines (age spots)
  • Myxoid cysts

Cryotherapy may also be used for select small basal cell carcinomas and squamous cell carcinomas when surgical excision is not feasible, though this is less common. Application technique and duration vary by lesion type, depth, and location.

Pharmacokinetics

Nitrogen is a colorless, odorless, inert gas that comprises approximately 78% of Earth's atmosphere. In medical applications, it is stored and used in its liquid state at extremely low temperatures.

Physical properties: Liquid nitrogen has a boiling point of -196°C (-320°F) at atmospheric pressure. It must be stored in specialized insulated containers (Dewar flasks) to maintain its liquid state. Upon contact with tissue at body temperature, rapid evaporation occurs.

Application methods include:

  • Cotton-tipped applicator (for small lesions)
  • Spray devices (cryoguns for larger areas)
  • Cryoprobe systems (for controlled application)

Tissue penetration: Freezing depth depends on application duration. A typical 10-20 second application creates a freeze zone extending 3-5 mm deep. The freeze ball (visible white frozen area) should extend 1-2 mm beyond the lesion margin for adequate treatment.

Healing timeline: Treated tissue undergoes necrosis over 24-72 hours, with blister formation common. Complete healing typically occurs within 2-4 weeks, though hypopigmentation may persist for months. There is no systemic absorption or metabolism, as nitrogen remains in gaseous form and disperses into the atmosphere.

Adverse effects

Cryotherapy with liquid nitrogen produces predictable local adverse effects. Most are self-limited but require patient counseling.

Common local reactions

  • Pain and burning during and immediately after application (universal)
  • Blister formation within 24 hours (expected, especially with aggressive treatment)
  • Erythema and edema surrounding treatment site
  • Serous or hemorrhagic drainage from blistered areas

Pigmentary changes

  • Hypopigmentation (most common long-term effect, may be permanent)
  • Hyperpigmentation (less common, usually temporary)
  • Particularly problematic in darker skin types (Fitzpatrick IV-VI)

Scarring and tissue damage

  • Hypertrophic scarring or atrophic scarring (rare with proper technique)
  • Nerve damage causing temporary or permanent sensory loss
  • Tendon or cartilage damage when treating lesions over these structures

Site-specific concerns

  • Perioral and periorbital treatment may cause prolonged edema
  • Treatment near nailfolds can cause permanent nail dystrophy
  • Digital nerve injury from aggressive treatment on fingers/toes

Infection

  • Secondary bacterial infection of blistered areas (uncommon)
  • Requires wound care instructions and monitoring

Systemic effects are extremely rare given the purely local application, but vasovagal syncope can occur during painful procedures.

Contraindications and warnings

Absolute contraindications

  • Cold intolerance syndromes: cryoglobulinemia, cold urticaria, Raynaud disease
  • Cold agglutinin disease
  • Areas with compromised circulation (peripheral vascular disease)
  • Suspected melanoma or other malignancies requiring histopathologic diagnosis

Relative contraindications

  • Darker skin types (Fitzpatrick IV-VI) due to high risk of permanent hypopigmentation
  • Lesions in cosmetically sensitive areas where pigment change is unacceptable
  • Children (due to pain and cooperation issues)
  • Pregnancy (theoretical risk, though rarely used on pregnant patients)

Site-specific warnings

  • Avoid aggressive treatment over nerves (ulnar, peroneal, digital nerves)
  • Exercise caution over tendons and cartilage (ears, nose, dorsal hands/feet)
  • Do not treat lesions overlying major blood vessels
  • Periorbital lesions require experienced practitioner

Special populations

  • Diabetic patients: increased risk of poor healing and neuropathy
  • Immunocompromised patients: higher infection risk, delayed healing
  • Patients with keloid tendency: may worsen scarring

Diagnostic considerations

Never treat lesions suspicious for melanoma or other malignancies requiring tissue diagnosis. Cryotherapy destroys tissue architecture, preventing histopathologic examination. When diagnosis is uncertain, biopsy must precede treatment.

Drug interactions

Liquid nitrogen has no systemic drug interactions because it functions as a purely topical physical modality with no absorption or systemic distribution.

Considerations with concurrent therapies

Immunosuppressive medications (methotrexate, biologics, systemic corticosteroids) may impair wound healing following cryotherapy, though they are not contraindications. Delayed healing and increased infection risk should be anticipated.

Anticoagulant and antiplatelet therapy (warfarin, clopidogrel, aspirin) increases the risk of hemorrhagic blister formation but does not preclude treatment. Patients should be counseled about increased bleeding tendency.

Photosensitizing medications (tetracyclines, fluoroquinolones, thiazides) do not interact with cryotherapy itself but may complicate healing if sun exposure occurs on treated areas.

Topical agent considerations

Cryotherapy is often combined with or used sequentially with topical agents:

  • Salicylic acid (wart treatment): commonly used before or after cryotherapy
  • Imiquimod (actinic keratoses): may be used as adjunct therapy
  • 5-fluorouracil (field treatment): sequential use is safe

No specific timing requirements exist between cryotherapy and topical treatments, though allowing complete healing before initiating irritating topical agents is prudent.

Device interactions: Patients with implanted electronic devices (pacemakers, defibrillators) can safely receive cryotherapy, as there is no electromagnetic interference. However, caution is warranted if using electrocautery for hemostasis following cryotherapy in these patients.

Clinical pearls

Application technique

  • The freeze time determines depth: 10-15 seconds for superficial lesions, 20-30 seconds for deeper lesions
  • Two freeze-thaw cycles are more effective than a single prolonged freeze for warts and actinic keratoses
  • The visible freeze halo should extend 1-2 mm beyond lesion margins
  • Cotton-tipped applicators work well for small isolated lesions; spray technique is better for multiple or larger lesions

Wart treatment specifics

  • Paring down hyperkeratotic warts before treatment improves efficacy
  • Plantar warts require more aggressive treatment (longer freeze times) due to thick overlying keratin
  • Mosaic warts (clustered plantar warts) are particularly resistant and may require multiple treatment sessions
  • Treatment every 2-3 weeks is typical; up to 3-4 sessions may be needed

Actinic keratosis management

  • A single 5-10 second freeze is usually sufficient for thin actinic keratoses
  • Field cryotherapy for multiple lesions is effective but causes significant temporary inflammation
  • Post-treatment erythema and crusting for 1-2 weeks is expected

Minimizing complications

  • Warn patients about expected pain, blistering, and pigment changes before treatment
  • Use shorter freeze times in cosmetically sensitive areas and darker skin types
  • Avoid treating over digital nerves (sides of fingers/toes)
  • Never treat pigmented lesions without definitive diagnosis

Comparison with other modalities

  • Cryotherapy vs. electrocautery: cryotherapy causes less scarring but may require more treatments
  • Cryotherapy vs. topical therapies: faster results but more acute inflammation
  • Cryotherapy is preferred for isolated lesions; topical field therapy better for multiple actinic keratoses

Medicolegal considerations

  • Document informed consent including risk of scarring and pigment changes
  • Photograph lesions before treatment when diagnosis might be questioned
  • Avoid treating lesions with atypical features without biopsy confirmation

Practice questions

1. A 45-year-old man with multiple actinic keratoses on his bald scalp undergoes liquid nitrogen cryotherapy. Three months later, he returns concerned about white spots where the lesions were treated. Examination reveals well-demarcated areas of hypopigmentation at previous treatment sites with no evidence of residual actinic keratoses. Which mechanism best explains this finding?

Answer: B. Hypopigmentation after cryotherapy results from direct cold-induced damage to melanocytes, which are highly sensitive to freezing temperatures. Melanocytes have limited regenerative capacity and may be permanently destroyed even when surrounding keratinocytes recover. This is the most common long-term adverse effect of cryotherapy. Post-inflammatory hypopigmentation is a distractor but typically resolves over months; the three-month timeframe and well-demarcated distribution specifically at treatment sites indicates direct melanocyte destruction rather than inflammatory change.

2. A 28-year-old woman with cryoglobulinemia presents with multiple common warts on her hands. She requests treatment with liquid nitrogen cryotherapy as her friend had successful wart removal with this method. What is the most appropriate management?

Answer: B. Cryoglobulinemia is an absolute contraindication to cryotherapy because exposure to cold can precipitate systemic symptoms including vascular occlusion, purpura, and organ damage due to cryoglobulin precipitation. Topical salicylic acid is a safe and effective alternative for wart treatment. Modified freeze times, test treatments, or optimizing cryoglobulin levels do not eliminate the fundamental risk. While electrocautery is also an option, the question stem asks for most appropriate management, and topical therapy is the safest first-line alternative for this common condition.

3. A 62-year-old man undergoes cryotherapy for a 6 mm pigmented lesion on his forearm that the provider diagnosed as seborrheic keratosis. Two weeks later, pathology from a biopsy of an adjacent similar-appearing lesion returns showing melanoma in situ. The treated lesion site shows only necrotic debris. What critical error was made in this case?

Answer: C. The critical error was treating a pigmented lesion with destructive cryotherapy without first obtaining histopathologic diagnosis. Any pigmented lesion with atypical features should be biopsied before destructive treatment because cryotherapy eliminates the tissue needed for diagnosis. In this case, melanoma was present, and the opportunity for pathologic diagnosis, staging, and appropriate definitive treatment of the treated lesion was lost. This represents both a diagnostic and medicolegal error. Freeze time adequacy and technique choices are irrelevant when the fundamental approach of destroying undiagnosed pigmented lesions is inappropriate.

Frequently asked questions

How does liquid nitrogen work for wart removal?

Liquid nitrogen destroys warts through rapid freezing at -196°C, which causes intracellular ice crystal formation that mechanically ruptures cell membranes and organelles. The extreme cold also damages blood vessels supplying the wart, leading to tissue ischemia and necrosis. A typical treatment involves two freeze-thaw cycles of 10-30 seconds each, with the frozen area extending slightly beyond the wart margin. Complete wart destruction usually requires 2-4 treatment sessions spaced 2-3 weeks apart, with healing occurring over 2-4 weeks after each session.

What are the side effects of cryotherapy with liquid nitrogen?

Common side effects include pain during application, blister formation within 24 hours, and temporary redness and swelling at the treatment site. The most significant long-term effect is hypopigmentation (lightening of skin color), which may be permanent, especially in darker skin types. Other potential effects include scarring, temporary or permanent nerve damage if applied over nerves, and nail dystrophy if treated near nailfolds. Infection of blistered areas is uncommon but possible. Pain is universal during treatment but typically resolves within hours.

Is liquid nitrogen cryotherapy safe during pregnancy?

Liquid nitrogen cryotherapy is generally considered low-risk during pregnancy because it has no systemic absorption and acts only locally on treated tissue. However, it is classified as a relative contraindication due to limited safety data and theoretical concerns. Most dermatologists prefer to defer elective cryotherapy treatments until after pregnancy unless medically necessary. For urgent indications such as rapidly growing lesions or confirmed premalignant conditions, the procedure can be performed with informed consent. The main practical concern is the pain and stress of the procedure rather than direct fetal harm.

Cryotherapy vs electrocautery — what is the difference?

Cryotherapy uses extreme cold (-196°C) to freeze and destroy tissue, while electrocautery uses electrical current to heat and burn tissue. Cryotherapy typically causes less scarring and is better for superficial lesions but may require multiple treatment sessions and causes more hypopigmentation. Electrocautery provides immediate tissue destruction in a single session with better hemostasis but produces more scarring and smoke. For warts, cryotherapy is generally preferred; for skin tags and vascular lesions, electrocautery may be more efficient. Neither method provides tissue for histopathology, so biopsy must be performed first if diagnosis is uncertain.

Why does liquid nitrogen cause hypopigmentation?

Liquid nitrogen causes hypopigmentation by damaging or destroying melanocytes (pigment-producing cells) in the treated area. Melanocytes are particularly sensitive to cold injury and may be permanently destroyed even when surrounding keratinocytes recover. The risk increases with longer freeze times, multiple freeze-thaw cycles, and in individuals with darker skin (Fitzpatrick types IV-VI). Hypopigmentation may become apparent weeks to months after treatment as inflammation resolves. Unfortunately, this pigment loss is often permanent because melanocytes have limited regenerative capacity. This risk must be discussed before treatment, especially in cosmetically sensitive areas.

Conditions it is used for

verruca vulgarisplantar wartsseborrheic keratosisactinic keratosisskin tagsmolluscum contagiosumlentigodermatofibroma
salicylic acidimiquimodfluorouracilpodophyllotoxincantharidintrichloroacetic acidtretinoiningenol mebutate

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: V03AN04

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.